''[[In vitro]]'' studies have shown that omadacycline has activity against a broad range of [[Gram-positive]] and select [[Gram-negative]] pathogens.<ref>{{cite journal|last1=Tanaka|first1=S. Ken|title=In Vitro and In Vivo Assessment of Cardiovascular Effects with Omadacycline|journal=Antimicrob. Agents Chemother.|volume=60|issue=9|pages=5247–53|date=20 June 2016|doi=10.1128/AAC.00320-16|pmid=27324778|pmc=4997885}}</ref>  Omadacycline has potent In Vitro activity against Gram-positive aerobic bacteria including [[Methicillin-resistant Staphylococcus aureus]] (MRSA), pencillin resistant and multi-drug resistant ''[[Streptococcus pneumoniae]]'' and [[Vancomycin-resistant Enterococcus|vancomycin-resistant ''Enterococcus'']].  Omadacycline has also shown activity against common Gram-negative aerobes, some anaerobes and atypical bacteria such as ''[[Legionella]]'' and ''[[Chlamydia]]''.<ref>{{cite journal|last1=Villano|first1=Stephen|title=Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections|journal=Future Microbiology|date=19 August 2016|doi=10.2217/fmb-2016-0100|url=http://www.futuremedicine.com/doi/pdf/10.2217/fmb-2016-0100|accessdate=24 August 2016|volume=11|pages=1421–1434}}</ref>   This activity translated to potent efficacy for omadacycline in an [[In vivo]] systemic infection model in mice.<ref>{{cite journal | doi = 10.1128/AAC.01242-13| pmid = 24295985| title = In Vitro and in Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline| journal = Antimicrobial Agents and Chemotherapy| volume = 58| issue = 2| pages = 1127–1135| year = 2013| last1 = MacOne| first1 = A. B.| last2 = Caruso| first2 = B. K.| last3 = Leahy| first3 = R. G.| last4 = Donatelli| first4 = J.| last5 = Weir| first5 = S.| last6 = Draper| first6 = M. P.| last7 = Tanaka| first7 = S. K.| last8 = Levy| first8 = S. B.| pmc=3910882}}</ref>
